Table 2.
Summary of Findings and Strength of Evidence.
| Outcome | No. of Patients (Trials) | RR (95%CI) | Absolute Effect Estimates (per 1000) | Quality of the Evidence | ||
|---|---|---|---|---|---|---|
| Control | Intervention | Difference | ||||
| Cancer mortality | 61882 (6) | 0.96 (0.80 to 1.16) | 22 | 21 | −1 (−4 to 4) | Moderate |
| Colorectal cancer mortality | 33849 (3) | 0.91 (0.49 to 1.67) | 2 | 2 | 0 (−1 to 2) | Moderate |
| Lung cancer mortality | 29288 (3) | 0.63 (0.45 to 0.90) | 6 | 4 | −2 (−1 to −3) | High |
| Breast cancer mortality | 40132 (3) | 1.04 (0.58 to 1.87) | 1 | 1 | 0 (0 to 1) | Moderate |
| Prostate cancer mortality | 26682 (2) | 0.6 (0.21 to 1.74) | 1 | 1 | 0 (−1 to 1) | Low |
| Cancer incidence | 51369 (11) | 0.99 (0.93 to 1.06) | 68 | 67 | −1 (−5 to 4) | High |
| Colorectal cancer incidence | 39494 (6) | 1.15 (0.89 to 1.49) | 6 | 7 | 1 (−1 to 3) | High |
| Lung cancer incidence | 34740 (4) | 0.94 (0.73 to 1.21) | 7 | 7 | 0 (−2 to 1) | High |
| Breast cancer incidence | 20175 (5) | 1.03 (0.84 to 1.27) | 18 | 18 | 1 (−3 to 5) | High |
| Prostate cancer incidence | 15023 (3) | 0.91 (0.76 to 1.09) | 34 | 33 | −1 (−11 to 12) | High |